Chimeric antigen receptor (CAR) T-cell therapy is one of the hottest advances in lymphoma treatment, but who should get it and what does the process look like? Allison Winter, MD, of the Cleveland Clinic helps answer those questions on the podcast. She joins Blood & Cancer host David H. Henry, MD, of the Pennsylvania Hospital, Philadelphia, to break down the side effects and look ahead to possible off-the-shelf products.
In Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, discusses optimism bias. She recalls a time when a patient’s drive for optimism affected what she told them and whether that was a good or bad thing.
Practice points:
CAR T-cell therapy use in lymphoma
Reference:
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017 Dec 28; 377:2531-44.
* * *
Show notes by Emily Bryer, DO, resident in the department of internal medicine, University of Pennsylvania, Philadelphia.
* * *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: podcasts@mdedge.com
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd
Ilana Yurkiewicz on Twitter: @ilanayurkiewicz
Create your
podcast in
minutes
It is Free